On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
patients.
You may search for diseases (indications), authors, medication,
study design (controlled study, open trial, case report etc.) and other criteria.
If you want to add a study or a case report please click
here. Studies and case reports will be checked by the IACM before publication in this database. Please do not forget to enter your e-mail address in the field "address of author" for any request.
| Title | THC improves appetite and reverses weight loss in AIDS patients |
|---|
| Author(s) | Dejesus E, Rodwick BM, Bowers D, Cohen CJ, Pearce D |
|---|
| Journal, Volume, Issue | J Int Assoc Physicians AIDS Care 2007;6(2):95-100. |
|---|
| Major outcome(s) | THC improved appetite and weight and reduced nausea |
|---|
|
| Indication | Nausea/vomiting;Appetite loss/weight loss;HIV/AIDS | Abstract |
|---|
| Medication | Delta-9-THC | Objective: To determine whether dronabinol affects appetite and weight status in patients living with HIV/AIDS. METHODS: A retrospective chart review was conducted to analyze weight and appetite changes and nausea status in patients with HIV/AIDS who received dronabinol for 3 to 12 months from January 11, 1993, to March 17, 2003. RESULTS: Of the 117 patients who lost weight before baseline, 63% maintained or gained weight. In patients receiving dronabinol for 1 year, the mean weight gain (+/- SD) was 3.7 +/- 10.6 lb. The percentage of patients experiencing loss of appetite decreased significantly from 71% at baseline to 26% at 1 month (P < .001) and continued to decline throughout the trial. The percentage of patients experiencing nausea at baseline (38%) decreased consistently from week 2 on; this change from baseline was significant at month 6 (P = .031). CONCLUSION: When taken for 3 months to 1 year, dronabinol significantly improves appetite and reverses weight loss in patients living with HIV/AIDS. |
|---|
| Route(s) | Oral |
|---|
| Dose(s) | |
|---|
| Duration (days) | 90-365 |
|---|
| Participants | 117 patients with HIV/AIDS |
|---|
| Design | Open study |
|---|
| Type of publication | Medical journal |
|---|
| Address of author(s) | Orlando Immunology Center, Orlando, Florida, edejesus@oicorlando.com. |
|---|
| Full text |
 |
|---|
